Korro Bio, Inc. Total Liabilities and Equity
Korro Bio, Inc. (KRRO) had Total Liabilities and Equity of $163.45 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-06
- 2026-06-30: Liabilities and Equity $163.45M.
- 2026-03-31: Liabilities and Equity $183.62M.
- 2025-12-31: Liabilities and Equity $113.51M.
- 2025-09-30: Liabilities and Equity $161.55M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $163.45M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $183.62M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $113.51M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $161.55M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $180.43M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $202.21M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $226.24M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $243.54M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $249.59M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $197.99M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $221.66M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $46.35M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $79.38M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $101.50M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $73.74M 10-K · filed 2024-03-26 | $121.24M 10-K · filed 2023-03-10 |
| 2022-09-30 | $136.01M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $149.66M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $164.94M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $185.36M 10-K · filed 2023-03-10 | |
| 2021-09-30 | $202.19M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $220.21M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $241.51M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $264.72M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $234.32M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $204.79M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $215.72M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $223.22M 10-K · filed 2021-03-29 | |
| 2019-09-30 | $170.85M 10-Q · filed 2019-11-18 | |
| 2018-12-31 | $44.55M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |